Elsevier

Fertility and Sterility

Volume 94, Issue 7, December 2010, Pages 2916-2919
Fertility and Sterility

Correspondence
A variant in the fibrillin-3 gene is associated with TGF-β and inhibin B levels in women with polycystic ovary syndrome

Presented at the NIH Specialized Cooperative Centers Program in Reproduction and Infertility Research (SCCPIR) Meeting, May 11–12, 2009, Chicago, Illinois; the 91st Annual Endocrine Society Meeting, June 10–13, 2009, Washington, DC; and the NIH Annual Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Scholars Meeting, November 16–17, 2009, Bethesda, Maryland.
https://doi.org/10.1016/j.fertnstert.2010.05.047Get rights and content
Under an Elsevier user license
open archive

In an attempt to evaluate the association between allele 8 (A8) of D19S884 in the fibrillin-3 gene and circulating transforming growth factor (TGF) β and inhibin levels in women with polycystic ovary syndrome (PCOS), we studied 120 similarly aged women from families with PCOS and compared 40 women with PCOS who did not have A8 (A8− PCOS) with 40 women with PCOS who had A8 (A8+ PCOS) and 40 normally menstruating women who did not have either PCOS or A8 (A8− Non-PCOS). A8− PCOS is associated with higher levels of TGF-β1 compared with A8+ PCOS or A8− Non-PCOS, similar levels of TGF-β2 compared with A8+ PCOS but lower levels of TGF-β2 compared with A8− Non-PCOS, and lower levels of inhibin B and aldosterone compared with A8+ PCOS.

Key Words

Polycystic ovary syndrome
TGF-β
inhibin
fibrillin
genetic association study
hyperandrogenism
insulin resistance

Cited by (0)

R.S.S. passed away during the preparation of this article.

N.R.-K. has nothing to disclose. A.R.K. has nothing to disclose. L.M.D. has nothing to disclose. K.G.E. has nothing to disclose. R.S.S. has nothing to disclose. R.S.L. has received study support from Solvay and a speaker honorarium from Merck-Serono.

Supported by National Institutes of Health (NIH) grant nos. K 12HD055882, “Career Development Program in Women's Health Research at Penn State” from the National Institute of Child Health and Human Development (NICHD), U54 HD34449, and General Clinical Research Center grant M01 RR10732 and construction grant C06 RR016499 to Pennsylvania State University. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NICHD or the NIH.

This project is funded, in part, under a grant with the Pennsylvania Department of Health using Tobacco Settlement Funds (RSL- SAP 41-000-26343). The Department specifically disclaims responsibility for any analyses, interpretations or conclusions.